Drug Interaction
Definition
A change in one drug's effect caused by another drug, by food or by a supplement. Compounds that slow gastric emptying can alter how fast an oral medicine is absorbed, which is a pharmacokinetic interaction rather than a pharmacodynamic one.
What this means for research sourcing
Volta compounds are research chemicals not intended for human consumption; safety terminology here is provided for research literacy.
Related Terms in Clinical & Safety
Washout Period
The interval left for a compound to clear before something else begins, conventionally five half-lives. Crossover trials are built around it, because carry-over from the first arm would contaminate the second.
Immunogenicity
The tendency of an administered peptide or protein to provoke an antibody response. Trials report it routinely, because antibodies can blunt a drug's effect and, less often, cause reactions of their own.
Anti-Drug Antibodies (ADA)
Antibodies raised against a peptide or protein given in an animal or clinical study. Neutralising ADA can cancel the effect of a biologic entirely, so assays for them are part of the standard safety package.
Anaphylaxis
A severe systemic allergic reaction with onset in seconds to minutes, affecting airway, breathing and circulation. It is rare with peptides, and the first-line emergency treatment in the literature is epinephrine.
Gastroparesis
Markedly delayed gastric emptying, with nausea, vomiting and early fullness. It is a recognised consequence of GLP-1 receptor agonist treatment and follows directly from the mechanism, which is slowing gastric motility.
Pancreatitis
Inflammation of the pancreas, presenting with severe abdominal pain and raised lipase. It is monitored as a potential adverse event across the incretin class and appears in the labels of approved GLP-1 receptor agonists.
Gallbladder Disease
Gallstones and cholecystitis, which appear more often in trials of GLP-1 receptor agonists than on placebo. The usual explanation is the rapid reduction in body weight participants in those studies undergo, which is itself a gallstone risk factor independently of any drug.
MedWatch
The FDA's programme for reporting adverse events and product problems, open to clinicians and to the public. It is the input side of US pharmacovigilance, and its reports are voluntary, which is why counts from it understate.
